UCB Announces 11 Inaugural Recipients of Annual Hidradenitis Suppurativa Scholarship™

• The UCB Hidradenitis Suppurativa Scholarship Program, launched in June 2026, provides scholarships for undergraduate and graduate studies and other career-building pathways to people living with hidradenitis suppurativa (HS) and immediate family members
• Informed by patient insights, this HS initiative builds on UCB's network of scholarship programs in myasthenia gravis and epilepsy 

ATLANTA, Nov. 12, 2026 /PRNewswire/ -- UCB, a global biopharmaceutical company, today announced 11 recipients of its inaugural UCB Hidradenitis Suppurativa Scholarship, awarding up to $10,000 per recipient to support educational and career goals.

Launched this year, the UCB Hidradenitis Suppurativa Scholarship Program supports high school seniors and older living with hidradenitis suppurativa (HS) and their immediate family members in pursuit of undergraduate and graduate studies, certification programs, trade schools, and other career-building pathways. Top recipients were recognized at a UCB reception at the 11th Annual Symposium on Hidradenitis Suppurativa Advances (SHSA) meeting in Tucson, Arizona on November 5. Beyond the physical manifestations of HS, this disease can also significantly impact people's lives, including at work and school.^1-3

"We are proud to celebrate the inaugural recipients of the UCB Hidradenitis Suppurativa Scholarship and support them as they pursue their goals and continue making an impact in their schools, professions, and communities," said Patty Fritz, Head of U.S. Corporate Affairs, UCB. "People living with HS bring valuable perspectives shaped by experiences that can include years of searching for answers and a diagnosis. This scholarship recognizes not only what they have overcome, but who they are, what they have accomplished, and the potential they have to pursue their goals and make a difference in their communities."

The 2026 UCB Hidradenitis Suppurativa Scholarship Recipients:

• Anthony D.
• Britney J.
• Delyah F.
• Derrick A.
• Giselle S.
• Kyndall G.
• Nicole S.
• Paige S.
• Rocio C.
• Tobi M.

Names of the recipients have been shared with their permission. Some recipients opted out of this recognition. 

Recipients are pursuing undergraduate, graduate, and career-building opportunities in fields including nursing, teaching, mechanical engineering, political science, psychology, environmental design, and medicine. Their current work is equally varied, ranging from expanding access to STEM and robotics education to providing meals, housing support, and essential supplies to people in need. For each recipient, experiences living with HS or supporting a family member with HS have helped shape their ambitions.

"For a long time, HS felt like something I had to hide. While it can bring physical and emotional challenges that are often invisible to others, it has also taught me patience with myself, resilience, and the importance of advocating for myself and making space for voices that often go unheard," said Nicole S., a 2026 UCB Hidradenitis Suppurativa Scholarship recipient. "I carry those lessons into everything I do, from the classroom to the career I'm building."

In addition to the annual HS Scholarship, as part of the company's broader scholarship initiatives, UCB offers annual scholarship programs to those living with myasthenia gravis (MG) or epilepsy.

Applications for the HS Scholarship will reopen in 2027. To learn more about the UCB Hidradenitis Suppurativa Scholarship Program, visit the website here. 

About hidradenitis suppurativa (HS)

Hidradenitis suppurativa (HS) is a chronic, painful, and potentially debilitating inflammatory skin disease associated with systemic manifestations.^4-5 Its main symptoms include nodules, abscesses and pus-discharging draining tunnels, or sinus tracts leading out of the skin, which typically occur in the armpits, groin and buttocks.^4-5 People living with HS may experience flare-ups and severe pain that can have a major impact on quality of life.^4-5

For further information, contact UCB:
Investor Relations
Yvonne Naughton
T +44.175.344.7521
email yvonne.naughton@ucb.com

Brand Communications
Nicole Herga
T +1.773.960.5349
email nicole.herga@ucb.com

About UCB 
UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With more than 9000 people in approximately 40 countries, the company generated revenue of € 7.7 billion in 2025. UCB is listed on Euronext Brussels (symbol: UCB). Follow us on X: @UCBUSA.

Forward-looking statements 
This document contains forward-looking statements, including, without limitation, statements containing the words "potential", "believes", "anticipates", "expects", "intends", "plans", "seeks", "estimates", "may", "will", "continue" and similar expressions. These forward-looking statements are based on current plans, estimates and beliefs of management. All statements, other than statements of historical facts, are statements that could be deemed forward-looking statements, including estimates of revenues, operating margins, capital expenditures, cash, other financial information, expected legal, arbitration, political, regulatory or clinical results or practices and other such estimates and results. By their nature, such forward-looking statements are not guaranteeing future performance and are subject to known and unknown risks, uncertainties, and assumptions which might cause the actual results, financial condition, performance or achievements of UCB, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements contained in this document.

Important factors that could result in such differences include but are not limited to: global spread and impacts of wars, pandemics and terrorism, the general geopolitical environment, climate change, changes in general economic, business and competitive conditions, the inability to obtain necessary regulatory approvals or to obtain them on acceptable terms or within expected timing, costs associated with research and development, changes in the prospects for products in the pipeline or under development by UCB, effects of future judicial decisions or governmental investigations, safety, quality, data integrity or manufacturing issues, supply chain disruption and business continuity risks; potential or actual data security and data privacy breaches, or disruptions of UCB's information technology systems, product liability claims, challenges to patent protection for products or product candidates, competition from other products including biosimilars or disruptive technologies/business models, changes in laws or regulations, exchange rate fluctuations, changes or uncertainties in laws and/or rules pertaining to tax and duties or the administration of such laws and/or rules, and hiring, retention and compliance of employees. There is no guarantee that new product candidates will be discovered or identified in the pipeline, or that new indications for existing products will be developed and approved. Movement from concept to commercial product is uncertain; preclinical results do not guarantee safety and efficacy of product candidates in humans. So far, the complexity of the human body cannot be reproduced in computer models, cell culture systems or animal models. The length of the timing to complete clinical trials and to get regulatory approval for product marketing has varied in the past and UCB expects similar unpredictability going forward. Products or potential products which are the subject of partnerships, joint ventures or licensing collaborations may be subject to disputes between the partners or may prove to be not as safe, effective or commercially successful as UCB may have believed at the start of such partnership. UCB's efforts to acquire other products or companies and to integrate the operations of such acquired companies may not be as successful as UCB may have believed at the moment of acquisition. Also, UCB or others could discover safety, side effects or manufacturing problems with its products and/or devices after they are marketed. The discovery of significant problems with a product similar to one of UCB's products that implicate an entire class of products may have a material adverse effect on sales of the entire class of affected products. Moreover, sales may be impacted by international and domestic trends toward managed care and health care cost containment, including pricing pressure, political and public scrutiny, customer and prescriber patterns or practices, and the reimbursement policies imposed by third-party payers as well as legislation affecting biopharmaceutical pricing and reimbursement activities and outcomes. Finally, a breakdown, cyberattack or information security breach could compromise the confidentiality, integrity and availability of UCB's data and systems.

Given these uncertainties, the public is cautioned not to place any undue reliance on such forward-looking statements. These forward-looking statements are made only as of the date of this document, and do not reflect any potential impacts from the evolving event or risk as mentioned above as well as any other adversity, unless indicated otherwise. The company continues to follow the development diligently to assess the financial significance of these events, as the case may be, to UCB.

UCB expressly disclaims any obligation to update any forward-looking statements in this document, either to confirm the actual results or to report or reflect any change in its forward-looking statements with regard thereto or any change in events, conditions or circumstances on which any such statement is based, unless such statement is required pursuant to applicable laws and regulations.

View original content to download multimedia:https://www.prnewswire.com/news-releases/ucb-announces-11-inaugural-recipients-of-annual-hidradenitis-suppurativa-scholarship-302937188.html

SOURCE UCB